anebulo.com (ANEB): שווי פעילות לרווח לפני ריבית, מסים ופחת

The visualization of Anebulo Pharmaceuticals (ANEB) market value on the GURU.Markets platform demonstrates an EV/EBITDA ratio of 0.00. The business relies on the development of unique treatments for cannabinoid poisoning, which ensures long-term revenue due to a lack of alternatives. Clinical trials have been outsourced to external CRO partners to protect patents, while the production of trial batches is conducted at strictly controlled GMP laboratories without technical downtime.

This ratio compares the total enterprise value with its operating profit before taxes and depreciation, allowing for the determination of the business's real value regardless of the capital structure. Analyzing the business valuation level via the EV/EBITDA ratio is critically important for stress-testing the assets of Anebulo Pharmaceuticals (ANEB), whose capitalization relies on a unique antidote for the therapy of cannabinoid intoxication.